Bazedoxifene: Difference between revisions

Latest revision as of 11:23, 23 March 2025

Selective estrogen receptor modulator

Bazedoxifene is a medication that belongs to the class of drugs known as selective estrogen receptor modulators (SERMs). It is primarily used in the treatment of osteoporosis in postmenopausal women. Bazedoxifene functions by mimicking the effects of estrogen on bone density, thereby reducing the risk of fractures.

Pharmacology[edit]

Bazedoxifene acts as an estrogen agonist on bone and lipid metabolism, while acting as an estrogen antagonist on uterine and breast tissues. This dual action helps in maintaining bone density and reducing the risk of breast and uterine cancer, which can be a concern with estrogen replacement therapy.

Mechanism of Action[edit]

Bazedoxifene binds to estrogen receptors and modulates their activity. In bone tissue, it acts as an agonist, promoting bone density and strength. In breast and uterine tissues, it acts as an antagonist, blocking the proliferative actions of estrogen, which helps in reducing the risk of cancer in these tissues.

Clinical Use[edit]

Bazedoxifene is primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women. It is often used in combination with conjugated estrogens to provide a comprehensive approach to managing menopausal symptoms and preventing bone loss.

Dosage and Administration[edit]

Bazedoxifene is administered orally, typically in a daily dose. The specific dosage may vary based on the combination with other medications and the individual patient's needs.

Side Effects[edit]

Common side effects of bazedoxifene include hot flashes, leg cramps, and an increased risk of venous thromboembolism. It is important for patients to discuss their medical history with their healthcare provider to assess the risk of these side effects.

Contraindications[edit]

Bazedoxifene is contraindicated in women with a history of venous thromboembolism, active or past history of breast cancer, and in those with known hypersensitivity to the drug.

Research and Development[edit]

Bazedoxifene has been studied in various clinical trials to assess its efficacy and safety in the treatment of osteoporosis. Ongoing research is exploring its potential use in other conditions related to estrogen deficiency.

Related pages[edit]

@@ Line 1: / Line 1: @@
-{{intro}}
+{{Short description|Selective estrogen receptor modulator}}
-Bazedoxifene (ba" ze dox' i feen) is a selective estrogen receptor modulator that is used to prevent osteoporosis in menopausal women and for treatment of moderate-to-severe vasomotor symptoms associated with menopause (hot flashes, sweating).
-{{moa}}
+[[File:Bazedoxifene.svg|Chemical structure of Bazedoxifene|thumb|right]]
-Bazedoxifene has estrogen-like effects (agonism) on bone and the cardiovascular system, but antiestrogen activity (antagonism) on breast and uterus tissue.  This differential activity is keyed to achieving the beneficial effects of estrogens on bone in decreasing bone resorption and turnover and thus preventing osteoporosis, but avoiding the potential harmful effects of estrogen stimulation of breast and uterine tissue.
-{{fda}}
+'''Bazedoxifene''' is a medication that belongs to the class of drugs known as selective estrogen receptor modulators (SERMs). It is primarily used in the treatment of osteoporosis in postmenopausal women. Bazedoxifene functions by mimicking the effects of estrogen on bone density, thereby reducing the risk of fractures.
-While bazedoxifene by itself is approved for use in several other countries of the world, in the United States it is approved only as a combination product with low doses of conjugated estrogens.  In short term trials the combination of bazedoxifene and estrogens was shown to decrease menopause associated hot flushes.  Longer term trials of this combination have documented its efficacy in preventing osteoporosis in postmenopausal women.  The fixed combination of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) was approved for use in the United States under the brand name Duavee in 2013.
-{{se}}
+==Pharmacology==
-Common side effects include muscle spasms, nausea, diarrhea, dyspepsia, dizziness and abdominal, throat and neck pain.  Potential long term, severe adverse events include deep venous thrombosis, pulmonary embolism and ischemic strokes and the possible long term effects of estrogens such as increased risk of breast, endometrial and ovarian cancer and gallbladder disease.
+Bazedoxifene acts as an estrogen agonist on bone and lipid metabolism, while acting as an estrogen antagonist on uterine and breast tissues. This dual action helps in maintaining bone density and reducing the risk of breast and uterine cancer, which can be a concern with estrogen replacement therapy.
-{{gynecologic agents}}
+===Mechanism of Action===
-{{coststubd}}
+Bazedoxifene binds to estrogen receptors and modulates their activity. In bone tissue, it acts as an agonist, promoting bone density and strength. In breast and uterine tissues, it acts as an antagonist, blocking the proliferative actions of estrogen, which helps in reducing the risk of cancer in these tissues.
-<gallery>
-File:Bazedoxifene.svg|Bazedoxifene
+==Clinical Use==
-File:Bazedoxifene-3D-balls.png|Bazedoxifene
+Bazedoxifene is primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women. It is often used in combination with conjugated estrogens to provide a comprehensive approach to managing menopausal symptoms and preventing bone loss.
-</gallery>
+===Dosage and Administration===
+Bazedoxifene is administered orally, typically in a daily dose. The specific dosage may vary based on the combination with other medications and the individual patient's needs.
+==Side Effects==
+Common side effects of bazedoxifene include hot flashes, leg cramps, and an increased risk of venous thromboembolism. It is important for patients to discuss their medical history with their healthcare provider to assess the risk of these side effects.
+==Contraindications==
+Bazedoxifene is contraindicated in women with a history of venous thromboembolism, active or past history of breast cancer, and in those with known hypersensitivity to the drug.
+[[File:Bazedoxifene-3D-balls.png|3D molecular model of Bazedoxifene|thumb|left]]
+==Research and Development==
+Bazedoxifene has been studied in various clinical trials to assess its efficacy and safety in the treatment of osteoporosis. Ongoing research is exploring its potential use in other conditions related to estrogen deficiency.
+==Related pages==
+* [[Osteoporosis]]
+* [[Selective estrogen receptor modulator]]
+* [[Menopause]]
+* [[Estrogen]]
+[[Category:Selective estrogen receptor modulators]]
+[[Category:Osteoporosis]]
+[[Category:Menopause]]